Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448552 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00448552 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 30 participants.
The verdict
NCT00448552, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving oxaliplatin together with capecitabine works in treating patients with relapsed or metastatic head and neck cancer.
Interventions
- DRUG oxaliplatin
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-02 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00448552
The ClinicalTrials.gov registry entry for NCT00448552 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00448552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00448552 about?
NCT00448552 is a clinical study titled "Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I...
What is the current status of trial NCT00448552?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-02. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00448552?
The interventions under investigation include: oxaliplatin (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00448552?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.